Skip to main content
Menu

Posts tagged with "Clinical Trials"

  • Clinical Trials

    The Vaccine Protocols

    We now have the official clinical trial designs for the three biggest and most advanced coronavirus vaccine trials: Moderna, Pfizer/BioNTech and Oxford/AstraZeneca. Now, as for you, J&J, Novavax, Merck, and all the others that are pushing into efficacy trials as fast as possible – don’t think for a moment that you won’t be exp… Read More
  • Clinical Trials

    Monoclonal Antibody Data

    We have a bit of human clinical data from the Eli Lilly/Abcellera collaboration to make a monoclonal antibody therapy against the coronavirus. A full paper is coming soon, the press release says, but for now it looks like this is all we have to go on. It’s a mixed assortment of news. On the cheerful… Read More
  • Clinical Trials

    Serious Adverse Event Time

    Lots of uncertainty in the vaccine world today: as many will have heard, the Oxford/AstraZeneca trial in the UK, the US, and Brazil has been paused due to a serious adverse event. The New York Times, citing a source with knowledge of the event, reported last night that this was transverse myelitis. And Nature has… Read More
  • Clinical Trials

    More Pfizer/BioNTech Data On Their Actual Vaccine Candidate

    When we last heard from the Pfizer/BioNTech vaccine program, they had picked a different candidate than the one that they had already published on (BNT162b1). Today they’ve released more data about the actual candidate, BNT162b2. And it seems pretty clear why they went with it. This preprint describes a head-to-head study (NCT04368728) betwe… Read More
  • Aging and Lifespan

    Unity Biotechnology and Senescent Cell Therapy

    Let’s have a look at the case of Unity Biotechnology, because this is a story that won’t get so many headlines. Unity has been investigating a really interesting but high-risk idea. It’s in the anti-aging field, so those two adjectives sort of apply by definition, and it’s the hypothesis that one of the problems is… Read More
  • Clinical Trials

    SinoPharm’s Inactivated Coronavirus Vaccine

    So now we have some clinical data on yet another category of vaccine: SinoPharm’s inactivated coronavirus candidate. This is one of the classic vaccine techniques, where an infectious virus is altered by some sort of protein-denaturing treatment (heating or reactive chemistry) to make it noninfectious. But such particles can retain enough of… Read More
  • Clinical Trials

    The Russian Vaccine

    Many will have heard Russia’s announcement that they have approved a coronavirus vaccine. I’ve already had several people ask me what I think of it, so let me be clear: I think it’s a ridiculous publicity stunt. If it’s supposed to make Russia look like some sort of biotechnology powerhouse, then as far as I’m… Read More
  • Clinical Trials

    Vaccine Data From Novavax

    Several days after making some headlines with a press release about the data, the Novavax vaccine effort has published on Medrxiv. The is the first look at human data we have at an approach using recombinant coronavirus proteins (plus an adjuvant, in this case a proprietary saponin natural product). The protein itself is produced in… Read More
  • Clinical Trials

    Coronavirus Challenges in Primates, Compared

    We have a sudden influx over the last few days of preclinical rhesus challenge studies with various coronavirus vaccines, and it’s only natural to try to compare them. I have worked up a table with all four of the current results and the previously reported SinoVac inactivated virus vaccine, whose rhesus challenge numbers were officially… Read More
  • Clinical Trials

    The Latest Repurposing News (Two Parter: IL-6 and Apilimod)

    As everyone knows, there have been a lot of attempts to repurpose existing therapies for the coronavirus pandemic. I’ve covered several of these along the way, but it’s time for some updates. The work that’s been going on not only adds to our knowledge about treatment for infected patients, but it should – ideally – Read More